Abstract: Objective To evaluate efficacy effects and toxicities of Docetaxel plus Cisplatin for patients with advanced non-small cell lung cancer and approach clinical factors which can affect the survival. Methods Forty-one patients with advanced non-small cell lung cancer were received docetaxel 75mg/m2 on day 1 and cisplatin 75mg/m2 on days 2 to 4.The cycle of regimen was repeated every 3 weeks.Response and toxicity were evaluated in patients who completed two cycles of chemotherapy at least. Results The overall response rate was 29.3% and the median survival time was 10.3 months.The predominant toxicities were inhibition of bone marrow,nausea,vomiting and baldness.Most of patients were well-tolerated.Log-rank test and Cox regression appear that the efficacy,TNM stages and weight of tumor decreases are important factors for prognosis of patients with good physical performance and gender.Age and pathological type are less important factors. Conclusion Among the chemotherapy methods for advanced non-small cell lung cancer,Docetaxel plus Cisplatin has significant response rate,and its toxicity is well-tolerated,which worths advanced study and applying in clinical works.The therapeutic effects,TNM stages of tumor and weight decreases are important factors for prognosis.